T 0648/13 (Anti-alphaOPGL-1 antibody/AMGEN) of 15.02.2018
- European Case Law Identifier
- ECLI:EP:BA:2018:T064813.20180215
- Date of decision
- 15 February 2018
- Case number
- T 0648/13
- Petition for review of
- -
- Application number
- 02749660.3
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Antibodies to OPGL
- Applicant name
- Amgen Fremont Inc.
Amgen Inc. - Opponent name
- Teva Pharmaceutical Industries Ltd.
- Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2)European Patent Convention Art 53(c)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 83European Patent Convention R 115(2)Rules of procedure of the Boards of Appeal Art 12(4)Rules of procedure of the Boards of Appeal Art 15(3)
- Keywords
- Main request - requirements of the EPC met (yes)
Late-filed line of argument and evidence - admission into the appeal proceedings (no) - Catchword
- -
- Citing cases
- T 1085/13
Order
For these reasons it is decided that:
1. The appeal of appellant II is dismissed.
2. The decision under appeal is set aside.
3. The case is remitted to the opposition division with the order to maintain the patent with the following claims and a description to be adapted thereto:
Claims 1 to 10 of the main request, filed as auxiliary request 20 with the letter of 15 December 2017.